

American firm to distribute pain relievers in India

27 March 2013 | News | By BioSpectrum Bureau

American firm to distribute pain relievers in India



An American biotechnology company, Nutra Pharma Corporation that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, has received notification that their patent and trademarks for its Nyloxin line of pain relievers have been published in India's Official Journal. This allows for patent and brand protection, leading to eventual sales through Indian distributors.

The company that markets several drug products for sale for the treatment of pain under the brands Cobroxin and Nyloxin, noted that its patent, "Use of Cobratoxin as an Analgesic," was published in the Official Journal No.: 09/2013 of the Indian Patent Office (IPO) on March 1, 2013. The Trademarks for Nyloxin are registered in India under Class 5, which represents a Pharmaceutical or a dietetic substances adapted for medical use.

"The patent and trademark publications in India represents one of the more significant international market opportunities for Nyloxin," said Mr Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Now that we have patent protection to protect our formulas and trademark protection to defend the brand we can work to create sales and distribution in India. With the population of India exceeding a billion people and with limited patient access to opioid-based pain relievers throughout the country, India represents a potentially significant customer base for Nyloxin," he concluded.

Nyloxin is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.

According to a 1998 study published in the Journal of the American Medical Association (JAMA), it was estimated that 19% of patients evaluated in India suffered from persistent pain. An additional 2007 report from the Journal of Pain and Symptom Management, documented that only 0.4% of India's population in need of opioids for pain relief had access to them.